Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicentre, Parallel Group, Open Label, Randomised Clinical Trial of Neoadjuvant Nivolumab and Ipilimumab Combined With Relatlimab for Patients With Resectable Advanced Melanoma Identified as Poor Responders to Immunotherapy

NCT06999980 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT06999980
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06999980 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicentre, Parallel Group, Open Label, Randomised Clinical Trial of Neoadjuvant Nivolumab and Ipilimumab Combined With Relatlimab for Patients With Resectable Advanced Melanoma Identified as Poor Responders to Immunotherapy
Lead sponsor
Melanoma Institute Australia
Phase
Phase 2
Overall status
Recruiting
Start date
February 9, 2026
Completion date
January 31, 2038
Enrollment
494 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cutaneous melanoma, mucosal melanoma